Tufnil (Tolfenamic Acid Tablet)

DSCRIPTION:-

Tatnil is a preparation of tolfenamic acid. It is an NSAID with anti inflammatory, analgesic and antipyretic effects.
Tolfenamic Acid acts by inhibiting prostaglandin and leukotriene synthesis.

INDICATION:-

Acute migraine

DOSAGE AND ADMINISTRATION:-

Adulte:-

200 mg when the first symptoms migraine appear. The treatment can be repeated once after 1-2 hours if
satisfactory response is not obtained.
Children:-

A paediatric dosage regimen has hot yet been established.

Eiderty :-

Nomal adult dose

CONTRAINDICATION:-

Toitenaimc acid is contraindicated in active peptic ulceration, significantly impaired kidney or liver function and in
patients in whom attacks of asthma, urticaria or acute rhinitis are precipitated by aspirin or ather NSAIDs.

SIDE-EFFECTS:-

Toffenamic acid is will to tolereted at the recommended dosage. The side effects include diarrhoea, nausea, epigastric pain,vomiting, dyspepsia isolated reports of gastric ulceration,
drug exanthema, erythema in the form of smarting during urination in males.The occurrence is correlated with the concentration of a metabolite
and is most probably due to local irritation of the urethra. Increased consumption of liquid or
reduction of the dose diminisihes the risk of smarting. The urine may, due to coloured metabolitis
become a little more lemon-coloured. As is the case with the use of other NSAIDs, the occasional side
effects include headache, vertigo, tremor, euphoria, fatigue, isolated cases af dyspnoea, pulmonary
infiltration,bronchospasm and anthma attack, isolated cases of thrombocytopenia, anemia and leucopenia, isoleted cases of reversible liver
function disturbances and toxic hepatitis.

PRECAUTIONS:-

As is he case with other NSAIDs, Totemamic Acid should be used with caution in patients with a history of gastrointestinal ulceration,or impaired liver or
kidney function.

USE IN PREGNANCY AND LACTATION.

Pregnancy:-

Reproduction studies in animals have not shown any signs af fetal damags. controlled studies in pregnant
women are not available. As is the case with the use or other NSAIDs, tolfenaimc Acid should not be given
in the last trimester, due to risks of premature closure of the ductus arteriosus and prolonged parturition.

Lactation:-

Tolfenamic acid is excreted to such a very small extent in mother s milk that it should be without risk
to the breast-fed baby.

DRUG INTERACTIONS:-

In patients treated with anticoagulants, close monitoring of blood coagulation is recommended. The effect of loop diuretics may be reduced.The effect of lithium may be increased.